Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ...

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targeted ...

Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer. The Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for adults ...

Based on LAURA Phase III trial results which showed TAGRISSO extended median progression-free survival by more than three years AstraZeneca’s TAGRISSO®(osimertinib) has been approved in the ...

New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer. AstraZeneca has been ...

The Rybrevant-Lazcluze combo lowered the risk of death by 23% compared with Tagrisso in an updated analysis of the phase 3 MARIPOSA trial in treatment-naïve, EGFR-mutated non-small cell lung ...

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable ...

Tagrisso in the treatment of certain type of lung cancer. The study, called MARIPOSA, showed that at three years of treatment, with a median follow up of 31.1 months, 61% of patients given the ...

Based on LAURA Phase III trial results which showed TAGRISSO extended median progression-free survival by more than three years WILMINGTON, Del., September 26, 2024--(BUSINESS WIRE)--AstraZeneca ...